Table II. Chemokine, growth factor, and IFN levels by group.
| Analyte | BOS (n = 14) | preBOS (n = 6) | Transient Impairment (n = 4) | cGVHD Controls (n = 3) | p Valuea |
|---|---|---|---|---|---|
| Chemokines | |||||
| CCL2 (MCP-1) | 101 ± 251 | 144 ± 165 | 112 ± 96 | 40 ± 25 | 0.24 |
| CCL3 (MIP-1α) | 14 ± 3 | 14 ± 2 | 17 ± 3 | 14 ± 2 | 0.78 |
| CCL4 (MIP-1β) | 13 ± 6 | 16 ± 11 | 9 ± 2 | 11 ± 2 | 0.01 b |
| CCL5 (RANTES) | 5 ± 5 | 9.03 ± 0 | 4 ± 2 | 9 ± 3 | 0.03 |
| CCL11 (Eotaxin) | 14 ± 2 | 17 ± 20 | 12 ± 4 | 14 ± 2 | 0.02 b |
| CCL19 (MIP-3β) | 18 ± 45 | 38 ± 34 | 10 ± 1 | 10 ± 8 | 0.06 |
| CCL20 (MIP-3α) | 11 ± 30 | 14 ± 149 | 11 ± 2 | 11 ± 4 | 0.14 |
| CXCL1 (GROα) | 1129 ± 1993 | 3478 ± 5306 | 307 ± 205 | 133 ± 298 | 0.06 |
| CXCL2 (GROβ/MIP-2) | 81 ± 156 | 107 ± 596 | 26 ± 28 | 25 ± 36 | 0.02 b |
| CXCL10 (IP-10) | 386 ± 2457 | 1706 ± 5433 | 180 ± 158 | 85 ± 1606 | 0.06 |
| Growth factors | |||||
| EGF | 483 ± 616 | 622 ± 1269 | 433 ± 540 | 214 ± 168 | 0.13 |
| FGF2 | 10 ± 5 | 21 ± 11 | 7 ± 1 | 7 ± 1 | 0.02 b |
| FLT3 ligand | 31 ± 42 | 55 ± 42 | 21 ± 4 | 19 ± 10 | <0.01 b |
| G-CSF | 44 ± 80 | 73 ± 842 | 31 ± 14 | 25 ± 68 | 0.30 |
| GM-CSF | 15 ± 20 | 24 ± 28 | 6 ± 1 | 7 ± 10 | 0.02 b |
| PDGF-AA | 905 ± 884 | 1340 ± 696 | 747 ± 690 | 414 ± 368 | 0.06 |
| PDGF-AB/BB | 13 ± 1 | 13 ± 0 | 11 ± 3 | 13 ± 2 | 0.03 |
| TGF-α | 14 ± 13 | 28 ± 26 | 9 ± 1 | 9 ± 3 | 0.01 b |
| VEGF | 691 ± 1336 | 1452 ± 502 | 479 ± 345 | 365 ± 258 | 0.02 b |
| IFNs | |||||
| IFN-α | 4 ± 0 | 4 ± 0 | 4 ± 2 | 4 ± 0 | 0.23 |
| IFN-β | 6 ± 3 | 9 ± 1 | 5 ± 1 | 6 ± 0 | 0.05 |
| IFN-γ | 16 ± 17 | 21 ± 24 | 18 ± 8 | 11 ± 5 | 0.18 |
a
Bold p values denote significant differences between preBOS and transient impairment.
b
Value is significant after multiple comparison testing using a beta-uniform mixture model.
BOS, bronchiolitis obliterans syndrome; cGVHD, chronic graft-versus-host disease; EGF, epidermal growth factor; FGF, fibroblast growth factor; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor.